ClinicaliQ Trial Snapshot
- Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) — Recruiting • Phase III • Oncology • NCT06074588.
- What is being tested: Sacituzumab tirumotecan (an antibody-drug conjugate targeting Trop-2) compared against standard chemotherapy (docetaxel or pemetrexed) in previously-treated advanced/metastatic nonsquamous NSCLC patients with EGFR mutations (exon 19 deletions or L858R).
- Patient eligibility overview: Adults with previously-treated advanced or metastatic nonsquamous NSCLC harbouring specific EGFR mutations (exon 19del or exon 21 L858R) who have progressed on prior therapy and are suitable for further systemic treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that…
Eligibility Snapshot
- The main inclusion and
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.